Keyword
in
Collection
Date
to
Houston Voice, No. 857, March 28, 1997
File 013
Citation
MLA
APA
Chicago/Turabian
Houston Voice, No. 857, March 28, 1997 - File 013. 1997-03-28. University of Houston Libraries. University of Houston Digital Library. Web. November 26, 2020. https://digital.lib.uh.edu/collection/montrose/item/4453/show/4428.

Disclaimer: This is a general citation for reference purposes. Please consult the most recent edition of your style manual for the proper formatting of the type of source you are citing. If the date given in the citation does not match the date on the digital item, use the more accurate date below the digital item.

(1997-03-28). Houston Voice, No. 857, March 28, 1997 - File 013. Montrose Voice. University of Houston Libraries. Retrieved from https://digital.lib.uh.edu/collection/montrose/item/4453/show/4428

Disclaimer: This is a general citation for reference purposes. Please consult the most recent edition of your style manual for the proper formatting of the type of source you are citing. If the date given in the citation does not match the date on the digital item, use the more accurate date below the digital item.

Houston Voice, No. 857, March 28, 1997 - File 013, 1997-03-28, Montrose Voice, University of Houston Libraries, accessed November 26, 2020, https://digital.lib.uh.edu/collection/montrose/item/4453/show/4428.

Disclaimer: This is a general citation for reference purposes. Please consult the most recent edition of your style manual for the proper formatting of the type of source you are citing. If the date given in the citation does not match the date on the digital item, use the more accurate date below the digital item.

URL
Embed Image
Compound Item Description
Title Houston Voice, No. 857, March 28, 1997
Contributor
  • Michelak, J. C.
Publisher Window Media
Date March 28, 1997
Language English
Subject
  • LGBTQ community
  • LGBTQ people
  • Gay liberation movement
Place
  • Houston, Texas
Genre
  • newspapers
Type
  • Text
Identifier OCLC: 31485329
Collection
  • University of Houston Libraries Special Collections
  • LGBT Research Collection
  • Montrose Voice
Rights In Copyright
Note This item was digitized from materials loaned by the Gulf Coast Archive and Museum (GCAM).
Item Description
Title File 013
Transcript I ABC Turns Down Homosexual Rights Group's Ad protest/ by David Bauder NEW YORK (AP) - A gay rights group that wanted to place an anti-discrimination television ad during the ■'Ellen" episode where the lead character reveals her homosexuality has been turned down by ABC. Despite the network rejection, the Human Rights campaign said a majority of local ABC affiliates it asked then agreed to run the commercial. The commercial depicts co-workers expressing surprise that a former colleague has been fired from a job because she is a lesbian. It is designed to build support for passage of a federal law banning job discrimination due to sexual orientation. ABCs rejection is ironic given its hopes that the April 30 "Ellen" episode, which will feature Oprah Winfrey, Laura Dem and k.d. lang, is a big ratings grabber, said David Smith, spokesman for the campaign. "They have determined that an actual depiction of a fact of life for gay people in this country falls under ihe judgment of controversial advertising," he said. "We strongly disagree with that judgment on their part. We believe they have made an error." ABC's decision is somewhat mitigated by its courage in permitting the "Ellen" story line and strong pro-gay corporate policies, he said. The network has a blanket policy against issue-oriented ads and this commercial fell into lhat category, said Janice Gretemeyer, ABC spokeswoman. "Topics of this nature are better discussed in news programs," she said. Smith's group went the more expensive route of trying to convince local affiliates to run the ad. Traditionally on a prime-time show, time is set aside for ads bought through the network and through the local affiliates. The Human Rights Campaign found that 59 of the 74 stations it asked agreed to run the ad. Seven affiliates turned it down and the rest didn't give an answer, Smith said. Ads were purchased in 29 markets, includ ing Boston, Denver, Los Angeles, San Francisco, Washington, Seattle and Bismarck, N.D. Cities where affiliates turned down the ad were Chicago; Houston; New York; Philadelphia; Wilmington, N.C; and Nashville and Knoxville, Tenn. "We basically don't take advocacy advertising," said Art Moore, spokesman for WABC- TV in New York City. The local ad buy will cost the campaign $175,000. A 30-second spot running nationally would have cost the same amount, Smith said. ABC's Ms. Gretemeyer also said there was no inconsistency between turning down the ad and the network's current month-long antidrug campaign. ABC has been pushing antidrug messages through public service announcements, news specials and story lines in some entertainment programs. "Public service spots are completely different from ads," she said. Advertisements do not include all the information about a prescription medication. Only your physician is qualified to decide if a prescription medication Is for you. ROXANE LABORATORIES. INC I Warning: May be MBit lorminy) -The ISAM name tor detta-9-ietraliydrooaiiiiabtnol (THC). Briel Summary mi Marinoi" l-Jronabinol) Capsules INDICATIONS ANO USAGE Mannol (dronabinol) rs indicated lor me treatment ot: 1 anotena associated with weight loss in pahents wtth AIOS; and 2 nausea and vomiting associated with cancer chemotherapy in patients who have tailed to respond adequately to conventional antiemetic treatments canMMBaiM Mannol (dronabinol) is contra indicated in any patient who has a history ol hypersensitivity to any cannabmoid or Mannol (dronabinol) is a medication with a potential tor abuse Physicians and pharmacists should use the same care in prescribing and accounting tor Mannol as they would with morphine oi other drugs controlled under Schedule II [Cll) ot the Controlled Substances Act. Because ot the nsk ot diversion, it is recommended that prescriptions be limited to the amount necessary for the penod between clinic visits Patients receiwrnfl freannerr! .vithi Manno. sncoid be specificalty ^«*med not to dfive. operate machineiv. ot engage in any hazardous activity until it is established that they are aMe to tolerate the drug and to perform such tasks safety PRECAUTIONS ll" '**-* -s 101)1*** medical conditions because of individual variabon in response and tolerance to the effects of Mannol Mannol should be used with caution in pabents with cardiac disorders because ol occasional hypotension, possible hypertension, syncope, or tachycardia (see CLINICAL PHARMACOLOGY). Mannol Should be used with caution in pahents with a history ot substance abuse, including alcohol abuse or dependence, because they may be more prone to abuse Matinol as well MuftpiesuOstanc* abuse is Mmimin and marijuana, which contains the same active compound, is a frequently abused substance Marinoi should be used with caution and careful psychiatric monitonng in patents with mania, depression, or schizophrenia because Mannol may enacerbate these illnesses. Marinoi should be used with caution in patients receiving concomitant therapy with sedatives, hypnoncs ot other psychoactive drugs because of the potential tor additive or synergistic CNS eflects Mannol Should De used with caution in pregnant patients nursing mothers, or pediatric patients because it has not been studied m these patent populations. Mannol should be used with cauhon for Ireatmenl of anorexia and weight loss in elderly patients with AIDS because they may be more sensitive to the psychoactive eflects and because its use m these pahents has not been studied. Information lor PalnnS: Patients receiving treatment wrth Mannol (dronabinol) should be alerted to the potential tor additive central nervous sysiem depression if Mannol is used concomitantly with alcohol or other CNS depressants such as benzodiazepines and barbiturates Patiems receiving treatment with Mannol should be specifically warned not to drive operate machinery, or engage in any hazardous activity until it rs established that they are able to tolerate me drug and to pertorni such tasks safely Patients using Mannol should be advised of possible changes in mood and cither adverse behavioral effects of Ihe drug so as to avoid panic In the event of such manifestations. Pabents should remain under the supervision of a responsible adult dunng m.tiai use of Mannol and following dosage adjustments Drag MenctiMB: In studies involving patients wuh AIDS and/or cancer, Marinoi [dronabinol) has been co-admrn- istered with a variety of medications (eg., cytotonc agents, ant!-infective agents, sedatives, or opioid analgesicsi without resulting in any elmeafly significant drug/drug interactions. Although no drufttirug interactions were discov- ered dunng the ;i*r*cai tnais af Manno :.-■'.e';^'".:v "'eiK- mth other ideations thieugt- Doit* metabolic and pharmacodynamic mechanisms Dronabinol is highly protein bound to plasma proteins, and therefore, might displace other protein-bound drugs Although (his displacement has not been confirmed in vivo, practitioners Should monitor patients for a change in dosage requirements when administenng dronabinol to patients receiving other highly protein-bound drugs Published reports ot drugidrug interactions involving cannaOinoiflS are summarized in the following table. CONCOMTrMTDRUG O.IMICAL EFFECT'S) Amphetamines, cocaine, other sympafhomeneK agents Additive hypertension, tachycardia, possibly cardiotoxicity Atropine scopolamine, antihistamines, other anticholinergic agents Additive or super-additive tachycardia, drowsiness AfiHtrifrtyline. amotapaie, desipramme other tricyclic antidepressants Additive tachycardia, hypertension, drowsiness Saroitiiiates, benzodiazepines ethanol. lithium, wonts. Buspirone, antitiislammes. muscle relaxants, other CNS depressants Additive drowsiness and CNS depression Disultiram A reversible hypomaiK reaction was reported in a 28 y/o man who smol&manitiaiTzaxTtinnedbydecha^ fluoxetine A 21 yio female with depression and bulimia receiving 20 mg/day fluoxetine X 4 wks Became hypomamc alter smoking marvia-m symptoms resoled atler 4 days Antipyme. Dafbrturates Decreased clearance ot Ihese agents, presumably ina competitive mtntuhon ot metabolism TneOOhymK Irwejsedthecvhymemeatiomsmntomd with smoking ol rruryuana: effect smiar to thai tofowmg smoking tobacco CirclMimiii. MMf'"". MmuwmM m\ Ferttrty: Carcinogenicity studies have nol been performed with dronabmof Mutagenicity testing of dronabinol was negative m an Ames test in a long-term study (77 days) m rats, oral admwstraoon of dronabinol at doses Of 30 to 150 mgynr. equivalent to 0 3 to 15 times maximum recommended human dose (MRHO) of 90 nig-in'/day m cancer patients or 2 to 10 times MRHD of 15 mtfm'/iJay in AIOS pabents, reduced ventral prostate, seminal vesicle and epuJWymal weights and caused a decrease m seminal fluid volume. Decreases in spermatogenesis, number 0* developing germ cells, and number of ifydig cells in the testis were also observed However, sperm count, mating success and testosterone levels were not affected. The significance of these annul findings in humans is not known. Ptt|M*cr Pregnancy Category C Reproduction studies with dronabinol have been performed in mice at 15 lo 450 mg/iW. equMfent to 0 2"to 5 bmes maximum recommended human dose (MRHD) of 90 mg,m'-day in cancer patients or 1 to 30 times MRHD of 15 mg/irrtday m AIOS pabents, and in rats al 74 to 295 mg/m- (equivalent to 08 to 3 tunes MRHD Of 90 mg/m' m cancer patients or 5 lo 20 tunes MRHD of 15 mg/m-Vday in AIDS patients] These studies have revealed no evidence of teratogenicity due to dronabinol At these dosages m mice and rats. dioratand decreased maternal weight gain and number ot viable pups and increased fetal mortality and early resorptions Such effects were dose dependent and less apparent at lower doses which produced less maternal tonicity There are no adequate and well-controlled studies in pregnant women Dronabinol should be used only if the potential benefit justifies the potential nsk to the fetus, ftrtei MtfNre Use of Mannol s iw recommendM «i nuisi^ in breast m*. dronabmot s concentrated in and secreted m human breast milk and is absorbed by the nursing baby Adverse experiences information summarized in the tables below was derived from wen-controlled ckn-cal trials conducted in lhe US and US territories involving 174 patients exposed to Marmc-l (dronabinol) Studies Of AIDS related weight loss nciuded 157 patients receiving dronabinol at a dose of 25 mg twice daily and G7 receiving placebo Studies ot different durations were combined by consderlng the hist occurrence ol events dunng the first 28 days Studies ot nausea and vomiting related to cancer chemoiherapy included 317 pahents receiving dronabinol and 58 receiving placebo. A cannabmoid dose-related "high' (easy laughing, elation and heightened awareness) has been reported by patients receiving Marinoi in both the antiemetic (24%) and the lower dose appetite sfimuiam clinical bWi (BK ■ (see CLINICAL TRIALS). The most frequently reported adveree experiences <i patients wim AIDS dunrigplaMbCKxxitroWainiialtiiteiiivolvrt the CNS and were reported by 33% of patients recemng Mannol About 25% ot patients reported a minor CNS adverse event during the first 2 weeks and about A% reported such an event each week for the nex! 6 weeks thereafter PROBABLY CAUSALLY RELATED: Incidence greater than 1V dates derived from clinical trials m AIDS-related anorexia (N=157) and chemotherapy-related nausea (N=317). Rates were genera y mghei n the ant errelic ise igiven m parentheses) BorfrasanaoieAsthenia. Cardiovascular Palpitations, tachycardia, vasodilation/taciai flush Digestive. Abdominal pain", nausea", vomiting' Nervous sysiem (Amnesia), anxiety/nervousness, (ataxia), confusion, depereonalOation, dizziness', euphoria', (haWucinaaicxi). paranoid reaction', somnolence', thinlongabnorma* ;e o( •-. o 10% • 1-K Cardiovascular Con-undtvitrs', hypotension ■ Digestive Diarrhea".fecal im Musculoskeletal: Myalgias Nervous sysiem: Depression, nightmares, speech difficulties, ttnniius Slan and Appendages: Flushing" Specta* senses Vision difficulties. :..:.N ■:,.■ a-*d cnemotherapy-re 'Incidence ot events 0.3% to 1% CAUSAL RELATIONSHIP UNKNOWN: Incidence less ttlin 1%. The clinical significance ot the association of these events with Mannol treatment is unknown but they are reported as alerting information for f- -'- Bodyasa whole. Chills headache, mal Digestive Anorexia, hepatic enzyme ek Respiratory: Cough, rhinitis, sinusitis. Skin and Appendages Sweat.ng Marinoi (dronabinol) is one of the psychoactive compounds present in cannabis, and is abusabie and controlled Schedule II (Cll) under the Controlled Substances Act. Both psychological and physiological dependence have "—n noted in healthy individuals receiving dronabinol, but addiction is uncommon and his only been seen alter Chronic abuse of cannabis has been associated with decrements in motivation, cognition, judgement, and perception. The etiology ol these impairments is unknot ton rattier than an isolated effect of the drug No such decrements in psychological, social or neurological status have been associated with the administration of Mannol for therapeutic purposes. In an open-label study in patients with AIDS who received Marinoi for up lo five months, no abuse, diversion or systematic change in personality or social functioning were observed despite the inclusion of a substantial number ol patients with a past history of drug abuse. An abstinence syndrome has been reported after the abrupt discontinuation of dronabinol m volunteers receiving dosages ol 210 mg/day for 12 to 16 consecutive days Wilhin 12 hours after discontinuation, these WUM manifested symptoms such as irritability, insomnia, and restlessness By approximately 24 hours post-droriabinol discontinuation, withdrawal symptoms intensified to include "hoi flashes", sweating, rhinonhea. loose stools, hiccoughs and anorexia. These withdrawal symptoms gradually dissipated over the next 48 hours Electroencephalographic changes consistent wilh the effects of drug withdrawal (hyperexcitatwn) were recorded in patients after abrupt dechallenge Pabents also complained of disturbed steep for several weeks after discontinuing therapy with high dosages ol dronabinol OVERDOSAGE Signs and symptoms following MILD Mannol (dronabinol) mtowauon include drowsiness, euphoria, heightened sensory awareness, altered time perception, reddened coniuncitva, dry mouth and tachycardia; following MODEfl- ATE intoxication include memory impairment, depersonalization, mood alteration, urinary retention, and reduced bowel motility, and fallowing SEVERE intoxication include decreased motor coordination, lethargy, slurred speech, and postural hypotension Apprehensive patients may experience panic reactions and seizures may occur in patients with existing seizure disorders. The estimated lethal human dose ot intravenous dronalwiol is 30 mj\g(21(»my70 kg) Signiticam CNS symptoms in antiemetic studies followed oral doses of 04 mg/kg (28 mg/70 kg) of Mannol Management: A potentially serious oral ingestion, it recent, should be managed with gul decontamination In unconscious patients with a secure airway, instil! activated charcoal (30 lo 100 g in adults. 1 to 2 g/kg in infants) via a nasogastric tube A saline cathartic or sorbitol may be added to the first dose ot activated charcoal Patients experiencing depressive, hallucinatory or psychotic reactions should be placed in a quiet area and offered reassurance. Benzodiazepines (5 to 10 mg diazepam po) may be used lor treatment of extreme agitation Hypotension usually responds to Trendelenburg position and IV fluids Pressors are rarely required DOSAGE WD ADMINISTRATION Appetite tfmtaltoii: Initially, 2 5 mg Mannol (dronabinol) should be administered orally twice daily <b i.d.). before lunch and supper For pabents unable to tolerate this 5 mg/Hay dosage ot Mannol. the dosage can be reduced to 2.5 mgrday, administered as a single dose m the evening or at bedtime If clinicalty indicated and in the absence of significant adverse effects, the dosage may De gradually increased to a maximum ol 20 mij/day Mannol. administered in divided oral doses Caution should be exeicised in estalabng the dosa™ of Mannol because of the increased frequency ot dose-related adverse experiences at higher dosages (see PRECAUTIONS) Antiemetic- Mannol is best administered at an initial dose of 5 mow, gwi 11D 3 hours pnor to lhe administration Of Chemotherapy, men every 2 to 4 hours after chemotherapy is given, lor a total of 4 to 6 doses/day Should the 5 mg/m' dose prove to be ineffective, and in the absence tf significant side effects, the dose may be escalated by 2 5 mffm* nciements to a maximum of 15 mo/nV per dose Caution should be exercised m Dose escalation, havener. as lhe incidence of disturbing psychotic symptoms increases significantly at maximum dose (see PRECAUTIONS) SAFETY AND HAWKING Mannol (dronab*nol) should be packaged in a weH-Oosed container and stored ina cool environment between 8" and 15'C (46" and SfTF) Protect from freezing No pamcular hazard lo health care workers handling the capsules has been identified Access to abusabie drugs such as Mannol presents an occupational hazard tor addiction in Ihe health care industry Routine procedures for handling controlled substances developed to protect lhe pubic may not be adequale lo protect health care workers Implementation of more effective accounting procedures and measures to appropriately restrict access to drugs ol this class may minimize the risk ol self-administration by health care providers HOWSUmtEO MABfNOL- CAPSULES (UrtxiabiMl Mlotion in sesame oi' In soft gelatin capsules) 2.5 mg white capwles (IMtfrfM RL). NDC M54-2601 11: Bottles ot 25 capsules NDC 0054-2601-21: Botbes ot 60 capsules NDC 0054*2601-25: Bottles ot 100 capsules 5 (ng «ark brwM catMln (MMtHM RL). NDC 0054-2602-11 Bottles ol 25 capsules NDC 0054-2602-25. Bottles of 100 capsules 1D mg gr-Mft capsnlei (MenHM RL). NDC 0054-2603-11 Botiiej ol 2S capsules NDC 0054-2603 21 Bottles ot 60 capsules MARIN0L* is a registered trademark ot Uramed Pharmaceuticals. In Inc under license from Ummed Pharmaceuticals. Inc Manufactured by Banner Pharmacaps Inc Chaisworth CA 91311 0EA ORDER FORM RE0UIRE0 Caulion: Federal law prohibits dispensing without prescription is marketed by Roxane Laboratories. 066 ©1997 Ro,ane Laborotones. Ii Roxane ■ RU. 19% !8428&W(2/97) from page 11 were 72 arrests, mostly for blocking traffic. ACT UP, whose first protest took place on Wall Street in 1987, has a history of headline-grabbing exploits. In 1989, 4,500 members of ACT UP and other groups ringed St. Patrick's Cathedral. Inside, as Cardinal John O'Connor celebrated Mass, some protesters chained themselves to pews, shouted and lay in the aisles. Two years later, protesters broke into the studios of "The CBS Evening News," one person leaped in front of Dan Rather at the start of the newscast. But fewer people have been participating, a fact people inside and outside the group blame on everything from the deaths of group leaders to ACT UP's own success. "There's been 10 years of AIDS activism and a lot of what ACT UP has been fighting for has been accomplished," said Stephen LeBlanc of the group's San Francisco chapter. Chicago OK's Benefits CHICAGO (AP) - The City Council voted Wednesday to give health insurance benefits to the same-sex domestic partners of city workers, while protesters sang hymns and said the politicians were condoning homosexuality. "We've allowed Sodomites to rule too much of our government today, and we say it's enough, and from this day forward you're going to see the hand of God," the Rev. Hiram Crawford of Israel Methodist Community Church said outside thc crowded council chambers. '' Bigotry and intolerance are always vile, but they are especially vile when they masquerade as religion and virtue," said gay activist Rich Garcia. The ordinance, which had the backing of Democratic Mayor Richard M. Daley, passed 32-18 after the council tabled a substitute ordinance that would have extended the same benefits to unmarried heterosexual partners. Supporters on the council called the ordinance a matter of fairness. But Alderman Brian Dougherty said it was bad public policy. "'This is special interest politics for a segment of society to make them feel good and let government legitimize their relationship, but tt doesn't advance thc public good," Dougherty said. Los Angeles, New York, San Francisco, Seattle, Toronto and Vancouver have similar ordinances, as does the western Chicago suburb of Oak Park, according to Loralie Van Sluys of Hewitt Associates, a Lincolnshire company that consults on and administers employee benefit and compensation programs. About 75 government agencies and about 425 other employers have extended insurance benefits to domestic partners of employees, she said. Chicago has about 40,000 employees and city officials expect 300 to 400 people to sign up for the benefits, costing about $800,000 a year, said city Budget Director Diane Aigotti. The substitute ordinance would have cost about $3 million, her office estimated. Companies have found participation rates of 1 percent or less when offering such benefits only to gay employees, Ms. Van Sluys said. The figure is low largely because many eligible people already have coverage through their own employers, she said. The Illinois Senate on Tuesday passed a measure requiring communities that extend employee benefits to same-sex domestic partners to give the same benefits to heterosexual couples who meet the same criteria. Sponsoring Sen. Walter Dudcyz, R-Chicago, says that's only fair, but critics say the bill was intended to make Chicago's ordinance so costly that thc city would not adopt it. The bill is awaiting action in the House, which is controlled by Democratic Speaker Michael Madigan of Chicago, a Daley ally. ■_i-_E_____________ i <-. -r h 3 "7
File Name uhlib_31485329_n857_012.jpg